

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529)**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

At scoping consultation, stakeholders highlighted that the use of crizotinib in the Cancer Drugs Fund was restricted in the managed access agreement to patients with a better performance status, indicative of lower disability.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will appraise crizotinib within its marketing authorisation and based on the available evidence.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

**Approved by Associate Director (name):** Ross Dent

**Date:** 24/01/2024